CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Is Cardiac Diastolic Dysfunction a Part of Post-Menopausal Syndrome? Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction Empagliflozin Increases Cardiac Energy Production in Diabetes - Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors Heart Failure With Improved Ejection Fraction-Is it Possible to Escape One’s Past? Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

Review ArticleVolume 71, Issue 14, April 2018

JOURNAL:J Am Coll Cardio. Article Link

Respiratory Syncytial Virus and Associations With Cardiovascular Disease in Adults

KS Ivey, KM Edwards, HK Talbot et al. Keywords: cardiac exacerbation; hospitalizations; respiratory syncytial virus

ABSTRACT


Respiratory syncytial virus (RSV) is historically known for causing respiratory illness in young children, but the appreciation of its impact on older adults is growing. Studies have shown that hospitalization for respiratory illness due to RSV is complicated by cardiovascular events in 14% to 22% of adult patients, including worsening congestive heart failure, acute coronary syndrome, and arrhythmias. Additionally, underlying cardiovascular disease is associated with hospitalization in 45% to 63% of adults with confirmed RSV. In summary, patients with cardiopulmonary disease have higher rates of health care utilization for RSV-related illness and worse outcomes. Patients with cardiovascular disease likely represent an important target population for the rapidly developing field of RSV vaccines.